Puma Biotechnology Inc (NASDAQ:PBYI) — Market Cap & Net Worth
Market Cap & Net Worth: Puma Biotechnology Inc (PBYI)
Puma Biotechnology Inc (NASDAQ:PBYI) has a market capitalization of $382.08 Million ($382.08 Million) as of September 17, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #13708 globally and #3305 in its home market, demonstrating a -3.14% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Puma Biotechnology Inc's stock price $9.25 by its total outstanding shares 50876487 (50.88 Million). Also see Puma Biotechnology Inc balance sheet assets for a full breakdown of the balance sheet.
Puma Biotechnology Inc Market Cap History: 2015 to 2026
Puma Biotechnology Inc's market capitalization history from 2015 to 2026. Data shows change from $3.99 Billion to $470.61 Million (-18.14% CAGR). Also see Puma Biotechnology Inc (PBYI) cash flow conversion for how efficiently the company converts equity into cash flow.
Index Memberships
Puma Biotechnology Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Dow Jones Biotechnology
DJUSBT
|
$1.16 Trillion | 0.03% | #25 of 39 |
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 0.01% | #373 of 976 |
|
NASDAQ Composite
IXIC
|
$41.74 Trillion | 0.00% | #1340 of 3165 |
Weight: Puma Biotechnology Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Puma Biotechnology Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Puma Biotechnology Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Puma Biotechnology Inc (PBYI) share price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
1.33x
Puma Biotechnology Inc's market cap is 1.33 times its annual revenue
Latest Price to Earnings (P/E) Ratio
9.73x
Puma Biotechnology Inc's market cap is 9.73 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $5.03 Billion | $27.70 Million | -$292.00 Million | 181.56x | N/A |
| 2018 | $1.04 Billion | $251.00 Million | -$113.60 Million | 4.12x | N/A |
| 2019 | $445.17 Million | $272.26 Million | -$75.59 Million | 1.64x | N/A |
| 2020 | $521.99 Million | $225.11 Million | -$59.99 Million | 2.32x | N/A |
| 2021 | $154.66 Million | $253.16 Million | -$29.13 Million | 0.61x | N/A |
| 2022 | $215.21 Million | $228.03 Million | $2.00K | 0.94x | 107603.77x |
| 2023 | $220.30 Million | $235.64 Million | $21.59 Million | 0.93x | 10.20x |
| 2024 | $155.17 Million | $230.47 Million | $30.28 Million | 0.67x | 5.12x |
| 2025 | $302.72 Million | $228.37 Million | $31.11 Million | 1.33x | 9.73x |
Competitor Companies of PBYI by Market Capitalization
Companies near Puma Biotechnology Inc in the global market cap rankings as of September 17, 2026. Review Puma Biotechnology Inc (PBYI) tangible net worth to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Puma Biotechnology Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #186 globally with a market cap of $130.44 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.29 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.82 Billion USD ( AU$84.54 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #506 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #186 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.44 Billion | $514.63 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.29 Billion | $774.11 |
| #457 | CSL Ltd | AU:CSL | $59.82 Billion | AU$174.26 |
| #506 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $143.77 |
Puma Biotechnology Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Puma Biotechnology Inc's market cap moved from $3.99 Billion to $ 470.61 Million, with a yearly change of -18.14%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $470.61 Million | +55.46% |
| 2025 | $302.72 Million | +95.08% |
| 2024 | $155.17 Million | -29.56% |
| 2023 | $220.30 Million | +2.36% |
| 2022 | $215.21 Million | +39.14% |
| 2021 | $154.66 Million | -70.37% |
| 2020 | $521.99 Million | +17.26% |
| 2019 | $445.17 Million | -57.00% |
| 2018 | $1.04 Billion | -79.41% |
| 2017 | $5.03 Billion | +221.99% |
| 2016 | $1.56 Billion | -60.84% |
| 2015 | $3.99 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of Puma Biotechnology Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $382.08 Million USD |
| MoneyControl | $382.08 Million USD |
| MarketWatch | $382.08 Million USD |
| marketcap.company | $382.08 Million USD |
| Reuters | $382.08 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Puma Biotechnology Inc
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined wit… Read more